Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy

NCT04068181 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04068181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2020
Completion date
February 26, 2024
Enrollment
72 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma